Rivoglitazone


Rivoglitazone
Systematic (IUPAC) name
5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl) methoxy]benzyl}-1,3-thiazolidine-2,4-dione
Identifiers
CAS number	185428-18-6
ATC code	?
PubChem	3055168
Chemical data
Formula	C₂₀H₁₉N₃O₄S
Mol. mass	397.448 g/mol
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes.^[1]

It is being developed by Daiichi Sankyo Co.

[edit] References

^ Schimke K, Davis TM (2007). "Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes". Curr Opin Investig Drugs 8 (4): 338–44. PMID 17458185.

v • d • e Oral antidiabetic drugs and Insulin analogs (A10)

Biguanides	Metformin

Sulfonylureas	Carbutamide, Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide

Alpha-glucosidase inhibitors	Acarbose, Miglitol, Voglibose

Thiazolidinediones (TZD)	Pioglitazone, Rivoglitazone^†, Rosiglitazone, Troglitazone^‡

Meglitinides	Nateglinide, Repaglinide, Mitiglinide

Dipeptidyl peptidase-4 (DPP-4) inhibitors	Alogliptin^†, Saxagliptin^†, Sitagliptin, Vildagliptin

Glucagon-like peptide-1 analog	Exenatide, Liraglutide^†, Albiglutide^†

Amylin analog	Pramlintide

Insulin analogs	fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir), Inhalable insulin (Exubera)

Dual PPAR agonists	Aleglitazar^†, Muraglitazar^§, Tesaglitazar^§

SGLT2 inhibitor	Dapagliflozin^†, Remogliflozin^†

^†Undergoing clinical trials. ^‡ Withdrawn from market. ^§Development halted.